Literature DB >> 8703877

Objective detection of hemifield and quadrantic field defects by visual evoked cortical potentials.

M S Bradnam1, D M Montgomery, A L Evans, D Keating, E A McClure, B E Damato, R McFadzean.   

Abstract

AIMS/
BACKGROUND: An objective method for detecting hemifield and quadrantic visual field defects has been developed using steady state visual evoked cortical potentials (VECPs), an adaptive noise canceller (ANC), and Hotelling's t2 statistic. The purpose of this study was to determine the sensitivity and specificity of the technique.
METHODS: Nine subjects (mean age 44 years) were investigated with field loss due to a variety of causes including both anterior and posterior visual pathway lesions. Dynamic perimetry was performed by means of a Goldmann or Tübingen perimeter. VECP recordings were made from each visual field quadrant (23 degrees X 23 degrees) by means of a steady state reversing checkerboard (7.7 rev/s). The central 5 degrees of the visual field and the vertical and horizontal meridians were masked during these measurements. Recordings were made from three electrode sites, positioned over the visual cortex, relative to a mid frontal electrode. Each recording lasted 2 minutes, during which time fixation was monitored. The data from each recording were divided into 4 second segments, and the amplitude and phase of the VECP signal measured using the ANC. Hotelling's t2 statistic was applied to determine the probability of signal detection. Receiver operating characteristic curves were used to find the optimum signal detection threshold for identification of the visual field defects.
RESULTS: The results of the study confirmed patterns of subjective visual field loss. The technique had a sensitivity and a specificity of 81% and 85%, respectively, for detecting 'non-seeing' areas in the inferior visual field, and 82% and 89%, respectively, for detecting 'non-seeing' areas in the superior visual field.
CONCLUSION: These results demonstrate that the technique is of potential clinical value to ophthalmologists and neurologists when subjective perimetry is not possible.

Entities:  

Mesh:

Year:  1996        PMID: 8703877      PMCID: PMC505452          DOI: 10.1136/bjo.80.4.297

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  17 in total

1.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

2.  Steady-state visual evoked cortical potentials from stimulation of visual field quadrants. Optimizing pattern variables for the size of the field to be investigated.

Authors:  M Bradnam; D Keating; D Montgomery; A Evans; B Damato; A Cluckie
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

3.  The pattern-evoked potential in compression of the anterior visual pathways.

Authors:  A M Halliday; E Halliday; A Kriss; W I McDonald; J Mushin
Journal:  Brain       Date:  1976-06       Impact factor: 13.501

4.  Visual field perimetry analysis using evoked potentials in normal and corpus callosum sectioned cats.

Authors:  A J Elberger; J D Spydell
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1985-03

Review 5.  Steady-state evoked potentials.

Authors:  D Regan
Journal:  J Opt Soc Am       Date:  1977-11

Review 6.  Evoked responses and the eye.

Authors:  N R Galloway
Journal:  Trans Ophthalmol Soc U K       Date:  1986

7.  Objective perimetry by evoked potential recording: limitations.

Authors:  D Regan; B A Milner
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1978-03

8.  The representation of the visual field in human striate cortex. A revision of the classic Holmes map.

Authors:  J C Horton; W F Hoyt
Journal:  Arch Ophthalmol       Date:  1991-06

9.  Visual evoked responses in the assessment of field defects in glaucoma.

Authors:  J M Cappin; S Nissim
Journal:  Arch Ophthalmol       Date:  1975-01

10.  Representation of the visual field in the occipital striate cortex.

Authors:  R McFadzean; D Brosnahan; D Hadley; E Mutlukan
Journal:  Br J Ophthalmol       Date:  1994-03       Impact factor: 4.638

View more
  8 in total

1.  Steady-state multifocal visual evoked potential (ssmfVEP) using dartboard stimulation as a possible tool for objective visual field assessment.

Authors:  Folkert K Horn; Franziska Selle; Bettina Hohberger; Jan Kremers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-09       Impact factor: 3.117

2.  Effect of simulated octant visual field defects on the visual evoked potential (VEP).

Authors:  Naveen K Yadav; Kenneth J Ciuffreda
Journal:  J Optom       Date:  2014-06-12

3.  Effect of different stimulus configurations on the visual evoked potential (VEP).

Authors:  Naveen K Yadav; Diana P Ludlam; Kenneth J Ciuffreda
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

4.  Multifocal Visual Evoked Potential (mfVEP) and Pattern-Reversal Visual Evoked Potential Changes in Patients with Visual Pathway Disorders: A Case Series.

Authors:  Daniah Alshowaeir; Con Yiannikas; Alexander Klistorner
Journal:  Neuroophthalmology       Date:  2015-08-25

5.  Objective perimetry using the multifocal visual evoked potential in central visual pathway lesions.

Authors:  A I Klistorner; S L Graham; J Grigg; C Balachandran
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

6.  Multifocal pattern VEP perimetry: analysis of sectoral waveforms.

Authors:  A I Klistorner; S L Graham
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 1.854

7.  Steady-State Visually Evoked Potentials Elicited by Multifrequency Pattern-Reversal Stimulation.

Authors:  Bettina Hohberger; Jan Kremers; Folkert K Horn
Journal:  Transl Vis Sci Technol       Date:  2019-02-28       Impact factor: 3.283

Review 8.  What can visual electrophysiology tell about possible visual-field defects in paediatric patients.

Authors:  Siân E Handley; Maja Šuštar; Manca Tekavčič Pompe
Journal:  Eye (Lond)       Date:  2021-07-16       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.